

# PHARMACOKINETICS AND BIOAVAILABILITY OF GENTAMICIN AFTER A SINGLE INTRAVENOUS AND INTRAMUSCULAR ADMINISTRATION IN CAMELS (*Camelus dromedarius*)

Yasser H. Al-Tarazi<sup>1</sup>, Hatim A. Elsheikh<sup>2</sup>, Ehab A. Abu-Basha<sup>3\*</sup> and Ahmad M. Al-Majali<sup>4</sup>

Department of Basic Veterinary Medical Sciences<sup>1&3</sup> and Clinical Sciences<sup>4</sup> Faculty of Veterinary Medicine

Jordan University of Science and Technology, P.O.Box 3030, Irbid 22110, JORDAN

Research Centre, MBC#: J-04 King Faisal Specialist Hospital and Research Centre-Jeddah<sup>2</sup>

P.O. Box 40047 Jeddah 21499, Kingdom of Saudi-Arabia

## ABSTRACT

The pharmacokinetics and bioavailability of gentamicin sulphate (3 mg/kg body weight) were studied in 5 healthy male camels (*Camelus dromedarius*) after a single intravenous (IV) and intramuscular (IM) administration according to a cross-over randomised design. Gentamicin concentrations were determined using a microbiological assay and *Bacillus subtilis* (ATCC 6633) as a test organism. The disposition curves were analysed using non-compartmental methods based on statistical moment theory. Following single IV administration, the elimination half-life ( $t_{1/2b}$ ), mean residence time (MRT), volume of distribution at steady state ( $V_{d_{ss}}$ ), volume of distribution ( $V_{d_{area}}$ ) and the total body clearance ( $Cl_B$ ) were  $5.98 \pm 0.42$  h,  $6.73 \pm 0.37$  h,  $0.28 \pm 0.02$  l/kg,  $0.36 \pm 0.02$  l/kg and  $0.71 \pm 0.02$  ml/min/kg, respectively. After a single IM administration, the maximum plasma concentrations ( $C_{max}$ ) was  $6.26 \pm 0.36$  mg/ml achieved at ( $t_{max}$ ) 2h post-injection time. The  $t_{1/2b}$ , MRT,  $V_{d_{area}}$ ,  $Cl_B$  and the absolute bioavailability (F) were  $5.24 \pm 0.31$  h,  $7.87 \pm 0.35$  h,  $0.42 \pm 0.03$  l/kg,  $0.95 \pm 0.05$  ml/min/kg and  $75.56 \pm 4.92\%$ , respectively. Based on these kinetics parameters, a dosage of 3 mg/kg by IM and IV administration every 24 h can be recommended for the treatment of bacterial infections in camels with  $MIC_{90}$  <sup>3</sup> 0.75 and 3.75 mg/ml, respectively.

**Key words:** *Bacillus subtilis*, bioavailability, camels, gentamicin, microbiological assay, pharmacokinetics

Gentamicin, a well-known aminoglycoside antibiotic, is widely used to treat serious bacterial infections in different species of animals including camels. It has broad-spectrum of activity against aerobic Gram-negative microorganisms such as *E. coli*, *Klebsiella* spp., *Pseudomonas aeruginosa*, *Salmonella* spp. and some Gram-positive bacterial species (Houdeshell *et al*, 1982; Gilbert, 1991). Gentamicin like other aminoglycosides displays a concentration-dependent bactericidal activity (Drusano, 2004). The peak drug concentration ( $C_{max}$ ) to minimum inhibitory concentration (MIC) ratio ( $C_{max}:MIC$ ) has been shown to be the most useful pharmacokinetics/pharmacodynamics (PK/PD) parameters for predicting clinical efficacy of aminoglycosides (Mckellar *et al*, 2004). Gentamicin concentration of not less than 8-10 fold of *in vitro* MIC is associated with effective bacterial killing (Gundersen *et al*, 2001; Albarelllos *et al*, 2004). Gentamicin has narrow range between toxic and therapeutic dose, therefore careful monitoring of plasma gentamicin levels

is indicated (Ladislav, 1999). Gentamicin is not absorbed from gastrointestinal tract; nevertheless it is rapidly absorbed after intramuscular (IM) and subcutaneous (SC) administration that revealed 70-100% bioavailability (Brown and Riviere, 1991; Riviere and Spoo, 1995).

Several pharmacokinetics data have been previously reported in different animal species including cattle (Ziv *et al*, 1982; Clarke *et al*, 1985), buffalo calves (Garg *et al*, 1991a, 1991b), sheep (Wilson *et al*, 1981; Brown *et al*, 1986), goats (Garg *et al*, 1995), horses (Pedersoli *et al*, 1980), dogs (Riviere and Coppoc, 1981), cats (Jernigan *et al*, 1988) and avian species (Haritova *et al*, 2004). Most of the drugs used in camels depends on PK/PD obtained from other species of animals. This due to lack of information about drug dosage regimens in the camels (Ali *et al*, 1996). The aim of the current study was to determine plasma concentrations and disposition kinetics of gentamicin in camels after a single IV and IM administration and to recommend a rational dosage schedule in camels.

SEND REPRINT REQUEST TO YASSER H. AL-TARAZI E-mail: tarazi@just.edu.jo

## Materials and Methods

### Animals

Five healthy male camels (*Camelus dromedarius*), 5-15 years old and weighing 450-700 kg, were used in this study. These were reared in a free-range in the eastern desert of Jordan. The animals were fed hay and had free access to water.

### Drugs

For IV and IM administration a commercially injectable gentamicin sulphate 4% (GENTAYET, SYVA Laboratories, SPAIN) was used. Working standard powder of gentamicin sulphate was obtained from Veterinary and Agricultural Products Manufacturing Co. Ltd, (VAPCO), Amman, Jordan and was used to prepare standard curves.

### Experimental design

Camels were given gentamicin sulphate in a cross-over randomised design with 21 days washout period to ensure complete clearance of the drug. Gentamicin was administered in a single dose of 3 mg/kg body weight (bw). The drug was intravenously injected into the jugular vein and intramuscularly into the lower 3rd region of the neck.

### Collection of samples

Blood samples (5 ml) were collected from the right jugular vein into heparinised tubes just before drug administration (pretreatment) and at 5, 10, 15, 30 minutes and at 1, 2, 3, 5, 8, 12, 18, 24 and 48 h after IV and at 0 (pretreatment), 10, 20, 30 minutes and 1, 1.5, 2, 3, 5, 8, 12, 18, 24 and 48 h after IM administration. Blood samples were centrifuged (1000g, 10 min, 4°C) and plasma stored at -20°C until assayed.

### Analytical procedure

Camel plasma samples were assayed for determination of gentamicin concentrations by microbiological assay using Mueller-Hinton agar (Difco Laboratories, Detroit, MI, USA) and *Bacillus subtilis* (ATCC 6633) as test organism as previously described (Tsai and Kondo, 2001). Prior to analysis Mueller-Hinton broth culture containing cell density  $10^8$  cfu/ml that match 0.5 Mcfarland standard was prepared. The assay agar medium was prepared to contain cell density  $10^6$  cfu/ml (1ml broth culture per 99 ml melted agar medium). The solutions for the standard curve were prepared by dissolving gentamicin sulphate in distilled water, in a measuring flask to obtain a concentration of 1000 µg/ml. Then double fold serial dilution was done in untreated camel plasma to cover a range from 0.01 to 100 µg/

ml. Five wells, 8 mm in diameter, were made in standard petri dishes (120 mm) containing inoculated 25 ml agar. Wells were filled with either plasma samples or gentamicin standard solutions in duplicate manner. Zones of inhibition were measured after 18 h of incubation at 37°C and the concentrations of gentamicin were calculated from the standard curve. The standard curve in camel plasma was linear from 0.2 to 100 µg/ml ( $R^2=0.99$ ). The limit of quantification was 0.2 µg/ml.

### Pharmacokinetics and Statistical Analysis

The pharmacokinetics analysis of the data was performed using non-compartmental analysis based on statistical moment theory according to the method described by Gibaldi and Perrier (1982), with the help of computerised Topfit® programme (Tanswell and Koup, 1993). The calculated parameters were area under plasma concentration-time curve (AUC) using linear trapezoid method; area under the first moment curve (AUMC); mean residence time (MRT), where  $MRT = AUMC/AUC$ ; volume of distribution ( $V_{d_{area}}$ ), where  $V_{d_{area}} = (dose/AUC) b$ ; total body clearance ( $Cl_B$ ), where  $Cl_B = dose/AUC$ ; apparent volume of distribution at steady state ( $V_{ss}$ ), where  $V_{ss} = MRT \times Cl_B$ ; elimination rate ( $k_{el}$ ) was determined by least-square regression analysis of terminal log-linear portions of the plasma concentration-time profile ( $k_{el} = 2.303 \times \text{slop}$ ); elimination half-life ( $t_{1/2b}$ ), where  $t_{1/2b} = 0.693/k_{el}$ ; the maximum concentration ( $C_{max}$ ) and the corresponding peak time ( $t_{max}$ ) were determined by the inspection of the individual drug plasma concentration-time profiles. The absolute bioavailability (F) was calculated as  $(AUC_{non-IV} / AUC_{IV}) \times 100$ . All data are expressed as mean  $\pm$  SE.

## Results

There were no identifiable reaction post gentamicin administration. The mean plasma concentration-time profiles of gentamicin (3 mg/kg bwt) after a single IV and IM administration are shown in Fig 1. Gentamicin was not detected at 24 h post drug administration for both routes in all tested camels plasma. Pharmacokinetics parameters of gentamicin (3 mg/kg bwt) obtained after single IV and IM administration are given in Table 1. After IV injection, the plasma gentamicin concentration was 30.12 µg/ml at 5 min post-injection. The elimination half-life ( $t_{1/2b}$ ), mean residence time (MRT), volume of distribution at steady state ( $V_{d_{ss}}$ ), volume of distribution ( $V_{d_{area}}$ ) and the total body clearance ( $Cl_B$ ) were  $5.98 \pm 0.42$  h,  $6.73 \pm 0.37$  h,  $0.28 \pm 0.02$  l/kg,  $0.36 \pm 0.02$  l/kg and  $0.71 \pm 0.02$  ml/min/kg, respectively.




Fig 1. Plasma concentration-time profile (mean  $\pm$  SE) of gentamicin after IV and IM administration of 3 mg/kg body weight. (n = 5)

**Table 1.** Pharmacokinetics parameters (mean  $\pm$  SE) of gentamicin (3 mg/kg bwt) in camels after a single IV and IM administration. (n=5).

Parameters	Units	IV	IM
$t_{1/2b}$	h	5.98 $\pm$ 0.42	5.24 $\pm$ 0.31
MRT	h	6.73 $\pm$ 0.37	7.87 $\pm$ 0.53
$Vd_{area}$	l/kg	0.36 $\pm$ 0.02	0.42 $\pm$ 0.03
$V_{ss}$	l/kg	0.28 $\pm$ 0.02	-
$CL_B$	ml/min/kg	0.71 $\pm$ 0.02	0.95 $\pm$ 0.05
$C_{max}$	$\mu$ g/ml	30.12 $\pm$ 0.00	6.26 $\pm$ 0.36
$t_{max}$	h	0.08 $\pm$ 0.00	2.00 $\pm$ 0.00
$AUC_{0-18}$	$\mu$ g.h/ml	64.59 $\pm$ 1.51	48.34 $\pm$ 2.57
$AUC_{0-8}$	$\mu$ g.h/ml	70.92 $\pm$ 1.81	53.42 $\pm$ 3.17
F	%	-	75.56 $\pm$ 4.92

After a single IM administration of gentamicin (3 mg/kg bwt), the drug reached a peak plasma concentration of 6.26 $\pm$ 0.36  $\mu$ g/ml at ( $t_{max}$ ) 2 h. The  $t_{1/2b}$ , MRT,  $Vd_{area}$ ,  $CL_B$  and the absolute bioavailability (F) were 5.24 $\pm$ 0.31 h, 7.87 $\pm$ 0.35 h, 0.42 $\pm$ 0.03 l/kg, 0.95 $\pm$ 0.05 ml/min/kg and 75.56 $\pm$ 4.92%, respectively.

## Discussion

Gentamicin was introduced in 1960 and still considered to be the drug of choice for treatment of serious aerobic Gram-negative infections in different animal species including camels (Ali, 1988). The economic importance of the camels obliged the researchers to target it in their pharmacological research. To our knowledge, there are few

pharmacokinetics studies that describe the disposition kinetics of gentamicin in camels after different route of administration. Therefore, the dosage of gentamicin used in camels was derived empirically from PK/PD data obtained from other species of animals mainly cattle (Ali *et al*, 1996). This procedure may lead to undesirable effect associated with toxicity (Ali and Hassan, 1986), decrease effectiveness of the drug (Oukessou, 1994) and problems related to public health (e.g. antibiotic residue). Accordingly, the important pharmacokinetics parameters have been calculated at a single dose of 3 mg/kg bwt in camels. The concentrations of gentamicin in camels plasma was determined using a microbiological assay. This method did not distinguish between different gentamicin components. Nevertheless, it measures the total bactericidal activity, which is useful in pharmacodynamic evaluation. The disposition curves of gentamicin (3 mg/kg bwt) after a single IV and IM administration in camels were best described by a non-compartmental model, based on statistical moment theory that permits an accurate calculation of the major pharmacokinetics parameters, avoiding problems encountered in curve fitting.

After a single IV administration of gentamicin (3 mg/kg bwt), the  $t_{1/2b}$ , (5.98 h) was similar to those reported in buffalo calves (Garg *et al*, 1991a) and different from those found in camels (Ziv *et al*, 1991), higher of lower cattle (Ziv *et al*, 1982; Clarke *et al*, 1985), sheep (Wilson *et al*, 1981; Brown *et al*, 1986), goats (Garg *et al*, 1995) and horses (Pedersoli *et al*, 1980).

The prolonged  $t_{1/2b}$  reported in the present study and study conducted by Garg *et al* (1991a) indicate that the drug tends to stay (MRT=6.73) for along time in camels and buffalo calves tissues. Whereas, the differences in  $t_{1/2b}$  may be due to drug formulation, dosage and interspecies variation. The value of  $V_{ss}$  (0.28) indicates a good extravascular distribution of the drug. This value was parallel to the respective values reported in horses (Pedersoli *et al*, 1980) and pigs (Riond and Riviere, 1988), and moderately higher than those reported in cattle (Clarke *et al*, 1985) and lower than those for sheep (Brown *et al*, 1986).

The  $Vd_{area}$  (0.36 l/kg) indicates the low distribution of gentamicin in the body. This small volume of distribution is parallel to those reported in camels (Ziv *et al*, 1991), buffalo calves (Garg *et al*, 1991a), cattle (Clarke *et al*, 1985), sheep (Wilson *et al*, 1981), pigs (Riond and Riviere, 1988) and horses (Pedersoli *et al*, 1980), and lower than those reported in 4-5 weeks old cattle (Ziv *et al*, 1982). Gentamicin was slowly cleared out of the body ( $Cl_B=0.71$  ml/min/kg). The reduction in total body clearance in camels may result from the low volume of distribution of gentamicin in the current study. However, these results are in agreement to those reported in sheep (Brown *et al*, 1986) and horses (Bowman *et al*, 1986) and slightly different from those reported in camels (Ziv *et al*, 1991) and cattle (Ziv *et al*, 1982; Clarke *et al*, 1985). The anatomical, biochemical and physiological features that differentiate the camel from other animal species may affect the disposition kinetics of the drugs in the body (Kadir *et al*, 1997). Camels urine is acidic (pH 6.3-7.2) with glomerular filtration rate (GFR) and urine flow of 0.55-0.65 ml/kg/min and 0.70-2.2 l/day, respectively. The nephron in camels is twice as long as that in cows and goats. Subsequently, a lot of water that filtered through the glomerulus will be reabsorbed and thus significantly reduce urine flow (Kumar *et al*, 1998). Moreover, GFR in camels is lower than recorded for other ruminant species (Benlamlah and Depomyers, 1989). In addition, camels have developed a special adaptation with a respect to water metabolism (Etzion and Yagil, 1986).

The curves obtained following single IM administration indicate a slow absorption rate of gentamicin, with a maximum plasma concentration ( $C_{max}$ ) of 6.26  $\mu$ g/ml achieved at 2 h ( $t_{max}$ ). These results are in agreement with those reported in camels (Ziv *et al*, 1991) and pony foals (Gronwall *et al*, 1988) and lower than those reported in buffalo calves (Garg *et al*, 1991b), cows (El-Sayed *et al*, 1989), goats (Garg *et al*, 1995), mares (Swan *et al*, 1995). The  $t_{1/2b}$  (5.24

h) was higher than those reported in buffalo calves (Garg *et al*, 1991b), cows (El-Sayed *et al*, 1989), goats (Garg *et al*, 1995), mares (Swan *et al*, 1995), and pony mares (Haddad *et al*, 1985). Gentamicin had a low volume of distribution ( $Vd_{area}=0.42$  l/kg) and slow body clearance ( $Cl_B=0.71$  ml/min/kg). These finding are in agreement with those reported in buffalo calves (Garg *et al*, 1991b) and different from those reported in pony mares (Haddad *et al*, 1985) and goats (Garg *et al*, 1995). Gentamicin clearance decreases as the body weight increases and therefore the dose must be reduced to avoid renal dysfunction (Riviere and Spoo, 1995). The bioavailability (F) of gentamicin after IM administration (75.56%) was within the expected range (70-100%) for aminoglycosides antibiotic. However, the calculated F gained in the current study was lower than those reported in camels (135%) (Ziv *et al*, 1991), goats (96%) (Garg *et al*, 1995), lactating cows (92%) (Haddad *et al*, 1986) and pony mares (87%) (Haddad *et al*, 1985) and higher than those reported in dehydrated camels (54%) (Ziv *et al*, 1991) and cows (70%) (El-Sayed *et al*, 1989). Site of injection and regional blood flow may slow or accelerate the absorption of the drug and subsequently may interfere with the  $C_{max}$  and  $t_{max}$  that lead eventually to significant variation in the AUC that affect the rate and bioavailability (F) of the drug in the body.

The success of antimicrobial therapy in veterinary as well as in human medicine is greatly determined by the integration between pharmacokinetics and pharmacodynamics (PK/PD) parameters. The PK/PD parameters that have been investigated and correlated with high drug efficacy for the concentration-dependent drugs are the AUC<sub>0-24</sub>:MIC and  $C_{max}$ :MIC of ratios  $\geq 100$  and  $\geq 8$ , respectively. Whereas, drug plasma concentration must exceed MIC by 1-5 for  $> 70\%$  of the inter-dosing interval for the time-dependent agents (Mckellar *et al*, 2004). Gentamicin is a concentration-dependent, whereby the antimicrobial drugs kill bacteria to a greater extent at increasing exposure concentration ( $C_{max}$ :MIC  $\geq 8$ ) (Gunderson *et al*, 2001; Albarelllos *et al*, 2004). The minimum inhibitory concentrations (MICs) of microorganisms isolates from camels that are susceptible to gentamicin have not been determined. Recently, we isolated different pathogens from pneumonic lungs of camels with MIC range 0.5-4, 0.25-4, 0.5-8 and 0.25-0.5  $\mu$ g/ml for *E. coli*, *Klebsiella* spp., *Pseudomonas aeruginosa* and *Staphylococcus aureus* isolates, respectively (Al-Tarazi and Elsheikh, submitted). The MIC value of 0.75  $\mu$ g/ml was used along with the  $C_{max}$  (6.26 and 30.12  $\mu$ g/ml for IM and IV, respectively) obtained in

this study for the purpose of calculation of surrogate marker. Accordingly, the  $C_{max}$ :MIC of 8.35 and 40.16 are obtained for gentamicin after IM and IV administration, respectively. Based on these kinetics parameters, a dosage of 3 mg/kg by IM and IV administration every 24 h can be recommended for the treatment of bacterial infection in camels with MIC<sub>90</sub> £ 0.75 and 3.75 µg/ml, respectively.

### Acknowledgement

The authors are grateful to the Faculty of Scientific Research, Jordan University of Science and Technology (JUST) for the funding of this study (Project number: 145/99).

### References

- Albarellos G, Montoya L, Ambros L, Kreil V, Hallu R and Rebuelto M (2004). Multiple once-daily dose pharmacokinetics and renal safety of gentamicin in dogs. *Journal of Veterinary Pharmacology and Therapeutics* 27:21-25.
- Ali BH, Oukessou M and Bashir AK (1996). Pharmacokinetic considerations in the camel (*Camelus dromedarius*): a review. *Comparative Biochemistry and Physiology* 115C:1-9.
- Ali BH (1988). Survey of some drugs commonly used in camels. *Veterinary Research Communications* 12:67-75. Ali BH and Hassan T (1986). Some observations on the toxicosis Iquarawi AA and Ali BH (2000). A survey of the literature (1995-1999) on the kinetics of drugs in camels (*Camelus dromedarius*). *Veterinary Research Communications* 24:245-260.
- Benlamlih S and Depomyers H (1989). Changes in endogenous urea recycling and the handling of renal urea in pregnant and lactating Sardi sheep kept on a constant feeding level. *Reproduction, Nutrition and Development* 30:227-235.
- Brown SA and Riviere JE (1991). Comparative pharmacokinetics of aminoglycoside antibiotics. *Journal of Veterinary Pharmacology and Therapeutics* 14:1-35.
- Brown SA, Coppoc GL and Riviere, JE (1986). Dose-dependent pharmacokinetics of gentamicin in sheep. *American Journal of Veterinary Research* 47:789-794.
- Bowman KF, Dix LP, Riord J and Riviere JE (1986). Prediction of pharmacokinetics profiles of ampicillin sodium, gentamicin sulfate, and combination ampicillin sodium-gentamicin sulfate in serum and synovia of healthy horses. *American Journal of Veterinary Research* 47:1590-1596.
- Clarke CR, Short CR, Hsu RC and Baggot JD (1985). Pharmacokinetics of gentamicin in the calf: developmental changes. *American Journal of Veterinary Research* 46:2461-2466.
- Drusano GL (2004). Antimicrobial pharmacodynamics: critical interactions of "bug and drug." *Nature Reviews Microbiology* 2:289-300.
- El-Sayed MGA, Hatem ME and El-Komy AA (1989). Disposition kinetics of gentamicin in normal and endometritic cows using a microbiological assay. *Deutsche Tierärztliche Wochenschrift* 96:412-415.
- Etzion Z and Yagil R (1986). Renal function in camels (*Camelus dromedarius*) following rapid rehydration. *Physiologica et Zoologica* 59:558-562.
- Garg SK, Verma SP and Garg BD (1991a). Disposition kinetics of gentamicin in buffalo calves (*Bubalus bubalis*) following single intravenous administration. *Journal of Veterinary Pharmacology and Therapeutics* 14:335-340.
- Garg SK, Verma SP and Garg BD (1991b). Pharmacokinetics and urinary excretion of gentamicin in *Bubalus bubalis* calves following intramuscular administration. *Research in Veterinary Science* 50:102-105.
- Garg SK, Verma SP and Uppal RP (1995). Pharmacokinetics of gentamicin following single-dose parenteral administration to goats. *British Veterinary Journal* 151:453-458.
- Gilbert DN (1991). Once-daily aminoglycoside therapy. *Antimicrobial Agents and Chemotherapy* 35:399-405.
- Gibaldi M, Perrier D (1982). Non-compartmental analysis based on statistical moment theory. In *Pharmacokinetics*, 2nd ed. pp. 409-417, Marcel Dekker, New York, USA.
- Gronwall R, Brown MP and Hobbs S (1988). Serum gentamicin concentrations and pharmacokinetics in 2-week-old pony foals after intramuscular administration. *Journal of Equine Veterinary Science* 8:205-207.
- Gunderson BW, Ross GH, Ibrahim KH and Rotschafer JC (2001). What do we really know about antibiotic pharmacodynamics. *Pharmacotherapy* 21:302-318.
- Haddad NS, Pedersoli WM, Ravis WR, Fazeli MH and Carson RL (1985). Combined pharmacokinetics of gentamicin in pony mares after a single intravenous and intramuscular administration. *American Journal of Veterinary Research* 46:2004-2007.
- Haddad NS, Ravis WR and Pedersoli WM (1986). Pharmacokinetics of single doses of gentamicin given by intravenous and intramuscular routes to lactating cows. *American Journal of Veterinary Research* 47:808-813.
- Haritova MA, Djeneva HA, Lashev LD, Sotirova PG, Grov BI and Dyankov VN (2004). Pharmacokinetics of gentamicin and apramycin in turkeys roosters and hens in the context of pharmacokinetic-pharmacodynamic relationships. *Journal of Veterinary Pharmacology and Therapeutics* 27:381-384.
- Houdeshell JW, Lamendola JF and Mc-Cracken JS (1982). Clinical pharmacology of aminoglycosides. *Modern Veterinary Practice* 63:619-621.
- Jernigan AD, Wilson RC, Hatch RC and Kemp DT (1988). Pharmacokinetics of gentamicin after intravenous, intramuscular, and subcutaneous administration in cats. *American Journal of Veterinary Research* 49:32-35.
- Kadir A, Ali BH, Alhadrami G, Bashir AK, Landoni MF and Lees P (1997). Phenylbutazone pharmacokinetics and bioavailability in the dromedary camel (*Camelus dromedarius*). *Journal of Veterinary Pharmacology and Therapeutics* 20:54-60.
- Kumar R, Singh AP, Kapoor M and Rai AK (1998). Pharmacokinetics, bioavailability and dosage regimen

- of sulphadiazine (SDZ) in camels (*Camelus dromedarius*). *Journal of Veterinary Pharmacology and Therapeutics* 21:393-399.
- Ladislav S (1999). Aminoglycoside antibiotics-Two decades of their HPLC bioanalysis. *Biomedical Chromatography* 13:3-10.
- Mckellar QA, Sanchez Brunt S F and Jones DG (2004). Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. *Journal of Veterinary Pharmacology and Therapeutics* 27:503-514.
- Oukessou M (1994). Kinetic disposition of flunixin meglumine in the camel. *Veterinary Research* 25:71-75.
- Pedersoli WM, Bemonte AA, Purohit RC and Ravis WR (1980). Pharmacokinetics of gentamicin in the horse. *American Journal of Veterinary Research* 41:351-354.
- Riond JL and Riviere JE (1988). Multiple intravenous dose pharmacokinetics and residue depletion profile of gentamicin in pigs. *Journal of Veterinary Pharmacology and Therapeutics* 11:210-214.
- Riviere JE and Coppoc GL (1981). Pharmacokinetics of gentamicin in the juvenile dog. *American Journal of Veterinary Research* 42:1621-1623.
- Riviere JE and Spoo JW (1995). *Veterinary Pharmacology and therapeutics*, 7<sup>th</sup> Edn, Iowa state University Press., Ames, Iowa. pp 806-810.
- Swan GE, Guthrie AJ and Mulders MS (1995). Single and multiple dose pharmacokinetics of gentamicin administered intravenously and intramuscularly in adult conditioned thoroughbred mares. *Journal of the South African Veterinary Association* 66:151-156.
- Tanswell P and Koup J (1993). TopFit: a PC-based pharmacokinetic/pharmacodynamic data analysis program. *International Journal of Clinical Pharmacology, Therapy, and Toxicology* 31:514-520.
- Tsai C and Kondo F (2001). Improved agar diffusion method for detecting residual antimicrobial agents. *Journal of Food Protection* 64:361-366.
- Wilson RC, Whelan SC and Coulter DB (1981). Kinetics of gentamicin after intravenous, intramuscular, and intratracheal administration in sheep. *American Journal of Veterinary Research* 42:1901-1932.
- Ziv G, Ben-Zvi Z. and Yagil R (1991). Disposition kinetics of gentamicin in the normal and dehydrated camel. *Acta Vet Scand Suppl* 87:110-113.
- Ziv G, Nouws JF, Van-Ginneken CA (1982). The pharmacokinetics and tissue levels of polymyxin B, colistin and gentamicin in calves. *Journal of Veterinary Pharmacology and Therapeutics* 5:45-58.